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Volume 51, Number 1 Abstracts 281excised down to the level of the deep muscle fascia from the knee to the
dorsum of the foot. The wound was covered with 12- to 16/1000-inch split
thickness skin grafts harvested from the ipsilateral leg. For those who
underwent elective toe amputations, toe disarticulation at the metatarsal-
phalangeal joint was combined with removal of the articular cartilage from
the metatarsal heads. Average follow-up was 3.5 years. During follow-up,
20% of the patients who underwent combined Charles procedure and
elective toe amputation experienced recurrent bouts of cellulitis of the foot
or leg, 50% required at least one operation for excision of crypts within the
skin-grafted areas, and none required more proximal amputations. In those
patients who did not undergo elective toe amputation, 83% had multiple
episodes of foot or leg cellulitis and 54% underwent at least one operation for
foot or leg excision of crypts, and 80% subsequently required amputation of
toes secondary to chronic ulceration, infection, or drainage fromweb spaces.
Two patients required more proximal amputation, including one below
knee amputation.
Comment: Those who care for patients with advanced lymphedema
realize that appropriate foot hygiene is the mainstay to reduce interdigital
entry lesions, but such care can be ineffective in the terminal stages of
lymphedema. These patients have deformity of the toes and limitedmobility.
The increased weight and volume of the affected limbs prevents them from
performing appropriate foot hygiene. This is an aggressive approach to the
treatment of end-stage lymphedema. Nevertheless, if a decision has been
made to perform a Charles procedure, the authors’ data suggest the addition
of toe amputations is reasonable.
Lipid Treatment Assessment Project 2: A Multinational Survey to
Evaluate the Proportion of Patients Achieving Low-Density Lipopro-
tein Cholesterol Goals
Waters DD, Brotons C, Chiang CW, et al, and the Lipid Treatment
Assessment Project 2 Investigators. Circulation 2009;120:28-34.
Conclusion: Lipid-lowering therapy is more successful now than a
decade ago.
Summary: Older studies assessing lipid-lowering therapy found most
patients did not reach their low-density lipoprotein (LDL) cholesterol goal.
The Lipid Treatment Assessment Project (L-TAP) was conducted in 1996
and 1997 among almost 5000 patients in the United States. The study
found the goal for LDL cholesterol was obtained in primary care settings in
only 38% overall, and in only 18% of patients with established coronary heart
disease (Arch Intern Med 2000;160:459-67). A similar European study
from 15 countries between 1999 and 2000 found only 42% of 5226 patients
with established coronary heart disease reached a total cholesterol goal of
193 mg/dL (Eur Heart J 2001;22:554-72). The current study, L-TAP 2,
is a survey performed in 10,000 patients from nine countries (United
States, Canada, Mexico, Brazil, Spain, The Netherlands, France, Taiwan,
and Korea) between September 2006 and April 2007. The primary end
point was defined as success rate in achieving appropriate LDL cholesterol
goals for the patients’ level of risk. The study could evaluate 9955 patients
(54% men; mean age, 62  12 years); of these 30% had coronary disease,
31% were diabetic, and 14% were current smokers. Treatment consisted of a
statin in 75%. The proportion of patients achieving LDL cholesterol goals
according to relevant national guidelines ranged from 47% to 84% across
countries. In low-, moderate-, and high-risk groups, mean respective LDL
cholesterol was 119, 109, and 91 mg/dL. The success rate for LDL
cholesterol goal achievement was 86% in low-risk patients, 74% in moderate-
risk patients, and 67% in high-risk patients (73% overall). Among coronary
heart patients with greater than two risk factors, only 30% attained the
optimal LDL cholesterol goal of 70 mg/dL.
Comment: The proportion of patients achieving LDL cholesterol
treatment goals is much higher than a decade ago. Overall, 73% of patients
reached their LDL cholesterol goal. This goal was met, however, in only 67%
of high-risk patients. The glass is both half-empty and half-full. Clearly, more
patients are meeting LDL cholesterol goals than they were a decade ago;
however, one-third of high-risk patients remain inadequately treated. More
aggressive treatment of patients not meeting goals and improving success
rates in underperforming countries, particularly with the high-risk patient,
has the potential to even further reduce cardiovascular morbidity and
mortality.
Long-Term Outcome of Prophylactic Coronary Revascularization in
CardiacHigh-Risk Patients UndergoingMajor Vascular Surgery (from
the randomized DECREASE-V pilot study)
Schouten O, van Kuijk JP, Flu WJ, and the Decrease Study Group. Am J
Cardiol 2009;103:897-901.
Conclusion: Preoperative coronary revascularization in high-risk pa-
tients undergoing major vascular surgery is not associated with improved
postoperative or improved long-term outcome compared with best medical
treatment.Summary: In both the Coronary Artery Revascularization Prophylaxis
(CARP) and the Dutch Echocardiographic Cardiac Risk Evaluation Apply-ing Stress Echocardiography (DECREASE) V trials, prophylactic coronary
revascularization performed preoperatively did not result in improved peri-
operative outcomes (J Am Coll Cardiol 2007;49:1763-9 and N Engl J Med
2004;351:2795-804). It had been postulated that vascular surgery after
coronary stent placement might lead to an increase in cardiac events second-
ary to in-stent thrombosis with withdrawal of Plavix or bleeding complica-
tions if Plavix was maintained. Such conditions might explain lack of
perioperative benefits. The authors postulated after the hazardous perioper-
ative period passed there may have been long-term benefit of prophylactic
coronary revascularization. There were 1880 patients scheduled for major
vascular surgery in the DECREASE-V trial. Of these, 430 had three or more
risk factors (age 70 years, angina pectoris, myocardial infarction, stroke,
heart failure, renal failure, or diabetes mellitus). Patients with more than
three risk factors underwent dobutamine echocardiography or nuclear stress
imaging. Those with stress-induced ischemia were randomly assigned to
additional revascularization. In total, 101 patients showed extensive isch-
emia, and 49 were assigned to revascularization and 52 to no revasculariza-
tion. At almost 3 years of follow-up, overall survival rate was 64% for patients
randomly assigned to no preoperative coronary revascularization vs 61% for
patients assigned to preoperative coronary revascularization (hazard risk
[HR], 1.18; 95% confidence interval [CI], 0.63-2.19; P .61). Survival free
of all-cause death nonfatal myocardial infarction and coronary revasculariza-
tion were also similar in both groups, 49% and 42%, respectively, for patients
allocated tomedical treatment or coronary revascularization (HR, 1.51; 95%
CI, 0.89-2.57; P  .13). Only two patients assigned to medical therapy
required coronary revascularization during follow-up. In the patients who
survived the first 30 days after surgery, there was no benefit of revascularization
on prevention of late cardiac events (HR, 1.35; 95% CI, 0.72-2.52; P .36).
Comment:Guidelines of the American College of Cardiology/American
Heart Association recommend coronary angiography in patients with high-
risk noninvasive test results, and myocardial revascularization should be
performed in patients with prognostic high-risk anatomy where long-term
outcome is likely improved. The results of this study, along with the results
of the CARP study, suggest that modification of these recommendations
should be considered with respect to vascular surgical patients. There is no
evidence prophylactic revascularization before vascular surgery in patients
with severe but stable coronary disease does any good to improve the
perioperative course or the long-term survival of these patients.
Aspirin in the Primary and Secondary Prevention of Vascular Disease:
Collaborative Meta-Analysis of Individual Participant Data from Ran-
domised Trials
Antithrombotic Trialists’ Collaboration. Lancet 2009;373:1849-60.
Conclusion: Primary prevention of vascular events with aspirin therapy
is of uncertain value because reduction in the vascular events may be offset by
an increase in major episodes of hemorrhage.
Summary: Patients at high risk for a vascular event because they already
have vascular occlusive disease seemed to be effectively treated with aspirin
therapy as a secondary prophylaxis. Secondary prevention results in a de-
crease in vascular events (nonfatal myocardial infarction, nonfatal stroke, or
vascular death) of about 25%. Major bleeding complications occur in about
an order of magnitude smaller than the reduction of vascular events in
patients treated with secondary prophylaxis. The benefits of antiplatelet
therapy for secondary prevention of vascular events therefore substantially
exceed the risk. Data, however, are much less clear for primary prevention in
patients without known vascular disease or previous vascular events. The
authors therefore undertook a meta-analysis of serious vascular events,
defined as myocardial infarction, stoke, or vascular death and major hemor-
rhage in six primary prevention trials (95,000 individuals at low average-risk,
660,000 person-years, 3534 serious vascular events) and in 16 secondary
prevention trials (17,000 individuals at high average-risk, 43,000 person-
years, 3306 serious adverse events). They used an intention to treat analysis
and first events during the scheduled treatment period as end points. In
primary prevention trials, aspirin allocation yielded a 12% proportional
reduction in serious vascular events (0.5% aspirin vs 0.57% control per year,
P  .0001). This was due mainly to about a 20% reduction in nonfatal
myocardial infarction (0.18% vs 0.23% per year, P  .001). That effect was
not significant for stroke. Aspirin allocation increased major gastrointestinal
and extracranial hemorrhages (0.1% vs 0.07% per year, P  .0001). In
secondary prevention trials, aspirin allocation showed greater absolute re-
duction in serious vascular events (6.7% vs 8.2% per year, P .0001). There
was a nonsignificant increase in hemorrhagic stroke but a reduction of about
20% in total stroke (2.8% vs 2.54% per year, P .002). A reduction of about
a 20% was also documented in coronary events (4.3% vs 5.3% per year, P 
.001).
Comment: This analysis reaffirms the beneficial effects of aspirin for
secondary prevention of vascular events. However, it calls into significant
question the use of aspirin as primary prevention therapy in the “worried
well.” Additional trials of aspirin as primary preventive therapy are currently
in progress.
